Immunotech Biopharm Ltd (HK:6978) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immunotech Biopharm Ltd has announced the transfer of its RMB300 million Convertible Bonds from Tasly (Hong Kong) Pharmaceutical Investment Limited to Tibet Jiaze Venture Capital Co., Ltd, pending several conditions. The transfer reflects strategic movements in the financial market and highlights the venture capital interest in biotech industries. Upon completion, the bonds’ terms will remain unchanged, maintaining the financial stability of the arrangement.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.